Controlled trial of antituberculous chemotherapy in Crohn’s disease: a five year follow up study

Abstract

The absence of any benefit at the end of the initial two year trial period, and during the three year subsequent follow up, fails to support the hypothesis that mycobacteria play an important part in the pathogenesis of Crohn's disease, or that antituberculous chemotherapy may be of benefit.